The current standard of care for metastatic ER-positive/Her2 negative breast cancer utilizes the combination of either the estrogen receptor degrader Fulvestrant or aromatase inhibitors such as letrozole with CDK4/6 inhibitors such as Palbociclib (6, 7). The gene discussed is CYP19A1; the disease is breast cancer.